RBC cuts Angiotech price target

RBC Capital Markets has slashed its price target on Angiotech Pharmaceuticals (NASDAQ:ANPI; TSX:ANP) to 10 cents (U.S.) from 50 cents, while maintaining an “underperform speculative risk” rating in the wake of the company’s massive recapitalization plan to address its debt load. The stock dropped 22%, closing at 29 cents on Monday. Analyst Doug Miehm writes [...]

In conversation with Marc Létourneau

Marc Létourneau is very well known among the senior management and boards of directors of many emerging growth companies.  An accomplished investment banker with over 20 years of experience providing strategic advice, raising capital and negotiating mergers and acquisitions in both domestic and international markets, he has played a key role in shaping the current [...]

Patheon discussions with Lonza terminated

Lonza Group, a Swiss drugs industry supplier, has withdrawn a $460-million (U.S.) offer to acquire Mississauga-based contract drug manufacturer Patheon (TSX:PTI), citing the opposition of majority shareholder JLL Patheon Holdings, a U.S. private equity company. Earlier this year, Patheon rejected an unsolicited takeover bid from JLL, which holds a 57% stake in Patheon, as being [...]